Onconova Therapeutics Inc. (NASDAQ:ONTX) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $5.50 for the company, according to Zacks. Zacks has also given Onconova Therapeutics an industry rank of 89 out of 265 based on the ratings given to its competitors.
Separately, Maxim Group reaffirmed a “buy” rating and issued a $6.00 target price on shares of Onconova Therapeutics in a research note on Monday, September 26th.
Shares of Onconova Therapeutics (NASDAQ:ONTX) opened at 2.41 on Friday. Onconova Therapeutics has a 1-year low of $2.11 and a 1-year high of $8.17. The stock’s market capitalization is $16.29 million. The company has a 50-day moving average of $2.49 and a 200-day moving average of $3.07.
Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings data on Monday, November 14th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.53. The company had revenue of $1.70 million for the quarter, compared to analyst estimates of $1.60 million. Onconova Therapeutics had a negative return on equity of 148.52% and a negative net margin of 73.67%. On average, equities research analysts expect that Onconova Therapeutics will post ($5.91) EPS for the current fiscal year.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Get a free copy of the Zacks research report on Onconova Therapeutics (ONTX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com